beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.
In patients with amyloid beta-related cerebrovascular disorders, e.g. , Alzheimer's disease, one finds increased deposition of amyloid peptide (Abeta) and increased presence of monocyte/microglia cells in the brain. However, relatively little is known of the role of Abeta in the trafficking of monocytes across the blood-brain barrier (BBB). Our studies show that interaction of Abeta(1-40) with monolayer of human brain endothelial cells results in augmented adhesion and transendothelial migration of monocytic cells (THP-1 and HL-60) and peripheral blood monocytes. The Abeta-mediated migration of monocytes was inhibited by antibody to Abeta receptor (RAGE) and platelet endothelial cell adhesion molecule (PECAM-1). Additionally, Abeta-induced transendothelial migration of monocytes were inhibited by protein kinase C inhibitor and augmented by phosphatase inhibitor. We conclude that interaction of Abeta with RAGE expressed on brain endothelial cells initiates cellular signaling leading to the transendothelial migration of monocytes. We suggest that increased diapedesis of monocytes across the BBB in response to Abeta present either in the peripheral circulation or in the brain parenchyma may play a role in the pathophysiology of Abeta-related vascular disorder.
Giri
R
R
Departments of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA.
Shen
Y
Y
Stins
M
M
Du Yan
S
S
Schmidt
A M
AM
Stern
D
D
Kim
K S
KS
Zlokovic
B
B
Kalra
V K
VK
D000328:Adult; D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000906:Antibodies / Q000494:pharmacology; D000925:Anticoagulants / Q000493:pharmacokinetics; D001812:Blood-Brain Barrier / Q000276:immunology; D001921:Brain / Q000098:blood supply / Q000378:metabolism; D002196:Capillaries / Q000166:cytology / Q000378:metabolism; D002250:Carbon Radioisotopes; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003911:Dextrans / Q000493:pharmacokinetics; D004730:Endothelium, Vascular / Q000166:cytology* / Q000276:immunology / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019833:Genistein / Q000494:pharmacology; D018922:HL-60 Cells / Q000166:cytology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007444:Inulin / Q000493:pharmacokinetics; D008301:Maleimides / Q000494:pharmacology; D009000:Monocytes / Q000166:cytology*; D010446:Peptide Fragments / Q000494:pharmacology*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000276:immunology*; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000276:immunology*
D016229:Amyloid beta-Peptides; D000893:Anti-Inflammatory Agents; D000906:Antibodies; D000925:Anticoagulants; D002250:Carbon Radioisotopes; D003911:Dextrans; D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D010446:Peptide Fragments; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C078592:amyloid beta-protein (1-40); D007444:Inulin; D019833:Genistein; C070515:bisindolylmaleimide I